Taxus Cardium Pharmaceuticals Group Inc (CRXM)

[Antisemetic Asshole30]

Well, there is a hundred of such biotechs with no revenues just the future potential and (CXM) is not an exception. Or is it?
It depends whom you ask but if you read this so it must be you want to know why I hold 100,000 shares. First of all it's still cheap, second their clinical trials are in the last stages of development, there is no better time to buy than before the final announcement and commercialization of their products. And third reason I will know in the beginning of October when my banker will be back from a conference in Zurich where Cardium Therapeutics will present their potential of some clinical trials now being held in Russia. We are talking about the Phase 2B and Phase 3 clinical trials so when it will be completed, it will be too late to the party.
Also it's worth to mention that one of their portfolio companies InnerCool Therapies Inc. was sold to Royal Philips Electronics N.V. (PHG) 1 year ago for $11,000,000
If (PHG) thinks (CXM) is a good buy so do I, and what do you think?

Cardium Therapeutics, Inc. focuses on the acquisition and development of biomedical product opportunities and businesses that have the potential to address unmet medical needs, and definable pathways to partnering, commercialization, and other monetizations. Its investment portfolio includes the Tissue Repair Company and Cardium Biologics, which are medical technology companies primarily focused on the development of therapeutic products for wound healing, bone repair, and cardiovascular indications. Its product candidates include Generx, a DNA-based angiogenic growth factor therapeutic that is in phase 3 clinical trail for the treatment of patients with advanced coronary artery disease; Excellarate, a tissue repair's product candidate that is in Phase 2b clinical trial for the treatment of non-healing, neuropathic diabetic foot ulcers; and Excellagen, which is completed Phase 2b clinical trial for the treatment of chronically non-healing diabetic foot ulcers. The company was founded in 2003 and is headquartered in San Diego, California.

Links:

1. What exactly Philips bought for $11M and what it says about InnerCool Therapies and what in turn it says about (CXM)
http://www.newscenter.philips.com/main/standard/about/news/press/20090715_about_innercool.wpd

2. Bio Conference Zurich, 29-30 September, 2010
http://www.sachsforum.com/

http://www.cardiumthx.com/